clinical trial · NCT07873801
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Almirall, S.A.·phase3·not yet recruiting·n = 230
Atopic DermatitisLebrikizumabPlaceboLebrikizumabLebrikizumab
brief summary
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD outside of the face and neck region, and who are in need of systemic therapy.
started
Nov 1, 2026
primary completion
Feb 1, 2028
completion
Jun 1, 2028
last updated
Oct 14, 2026
official title
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Face and Neck Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol